Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04853017 · OUTCOME

The Proportion of Participants With Biomarker Reduction by Biomarker Type

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors · Source last updated 2025-09-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
6 months

What was measured

A biomarker reduction was any decrease from baseline in ctDNA and/or serum tumor antigen levels (CA19-9 or CEA).

Analysis population: All enrolled subject by biomarker type at baseline

Groups in this outcome

ctDNA Group

The ctDNA Group included subjects with detectable ctDNA at baseline.

Serum Tumor Biomarker Group

The Serum Tumor Biomarker Group included subjects who did not have detectable ctDNA at baseline, but did have either detectable CA19-9 or CEA.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ctDNA Group13
Serum Tumor Biomarker Group12

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ctDNA Group12Not reportedNot reportedNot reportedNot reported
Serum Tumor Biomarker Group9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        9
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    2. group Id
      OG001
      value
      12
    units
    Participants
description
A biomarker reduction was any decrease from baseline in ctDNA and/or serum tumor antigen levels (CA19-9 or CEA).
groups
  1. description
    The ctDNA Group included subjects with detectable ctDNA at baseline.
    id
    OG000
    title
    ctDNA Group
  2. description
    The Serum Tumor Biomarker Group included subjects who did not have detectable ctDNA at baseline, but did have either detectable CA19-9 or CEA.
    id
    OG001
    title
    Serum Tumor Biomarker Group
param Type
COUNT_OF_PARTICIPANTS
population Description
All enrolled subject by biomarker type at baseline
reporting Status
POSTED
time Frame
6 months
title
The Proportion of Participants With Biomarker Reduction by Biomarker Type
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice